NeuBase Therapeutics Says The Board Does Not Believe That Shareholder Value Will Be Enhanced By Issuing The Special $1 Per Share Dividend Its Shareholder Symetryx Requested In Their Press Release
Portfolio Pulse from Benzinga Newsdesk
NeuBase Therapeutics' board has rejected Symetryx's request for a special $1 per share dividend, stating it does not believe this will enhance shareholder value. The board and management will continue to engage in open and active dialogue with its shareholders, including Symetryx.
September 08, 2023 | 11:07 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
NeuBase Therapeutics' decision not to issue a special dividend as requested by Symetryx may cause dissatisfaction among shareholders, potentially impacting the stock negatively in the short term.
The decision by NeuBase Therapeutics' board not to issue a special dividend as requested by Symetryx could lead to dissatisfaction among shareholders. This could potentially lead to selling pressure on the stock, causing its price to decrease in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100